PT - JOURNAL ARTICLE AU - Daniela Stelzer AU - Franziska Ihle AU - Alexandra Weber AU - Nikolaus Kneidinger AU - Meis Tobias AU - Rene Schramm AU - Hauke Winter AU - Lorenz Frey AU - Michael Vogeser AU - Juergen Behr AU - Claus Neurohr TI - Azole plasma concentrations in lung transplant recipients DP - 2014 Sep 01 TA - European Respiratory Journal PG - P2460 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/P2460.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/P2460.full SO - Eur Respir J2014 Sep 01; 44 AB - Background:The absorption of azoles is subject to a high inter- and intra-individual variability. However, therapeutic drug monitoring [TDM] is not routinely performed. The purpose of this observation was to analyse azole plasma levels [APL] in lung transplant recipients [LTR].Methods:116 LTR of our lung transplantation [LTx] follow-up program who underwent TDM (65 male, 84 double-LTx, 3.1±3.5 years after LTx, age 49.7±14.9 years, underlying disease [ULD]: idiopathic pulmonary fibrosis [IPF; n=34; 29%], cystic fibrosis [CF; n=29; 25%], chronic obstructive pulmonary disease [COPD; n=28; 24%], other [n=25; 22%]) were evaluated. The target plasma levels [TPL] of azoles were defined as follows: Itraconazole [ITR] and Voriconazole [VOR] >1000µg/L, Posaconazole [POS] >700µg/L. APL were assayed using high performance liquid chromatography.Results:The mean APL for ITR, VOR, and POS were 715.4±866.1µg/L, 1649.2±1300.5µg/L and 903.4±780.9µg/L, respectively. Most frequent use was noted for ITR (n=55; 47%). The following results are classified by azole and ULD:View this table:Conclusion:Our data suggest that TDM is important to identify patients at risk for sub-therapeutic APL. Therefore, measuring plasma concentrations should be considered as part of the best practice management following LTx.